In a phase I study, the lack of efficacy of CC-90002, an anti-CD47 antibody led to the discontinuation of the clinical trial that targeted patients with refractory or relapsed AML or high-risk myelodysplastic syndromes. This evidence concerns the gene CD47 and myelodysplastic syndrome.